cas 20327-23-5|| where to buy 1-cyclopropylpiperazine

製品名:1-cyclopropylpiperazine

IUPAC Name:1-cyclopropylpiperazine

包装単位	有効在庫	価格（USD）
CM102401-10g	in stock	ɅȬ
CM102401-25g	in stock	ǊɅǧ
CM102401-100g	in stock	ȁǊƦ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 20327-23-5 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:20327-23-5; 分子式:C7H14N2; 融点:-; SMILESコード:N1(C2CC2)CCNCC1; 密度:

: カタログ番号:CM102401; 分子量:126.2; 沸点:200°C at 760 mmHg; MDL番号:MFCD06254805; 保管方法:Store at 2-8°C.

: Piperazines; Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

: Cyclopropanes; Cyclopropane is the smallest cyclic compound with unique structural features and physicochemical properties, which is widely used in the design of small molecule drugs. In drug design, it is often used to increase activity, fix conformation and improve PK and water solubility. The introduction of cyclopropyl groups into drugs can change various properties of molecules, such as improving metabolic stability; increasing biological activity; enhancing drug efficacy; limiting polypeptide conformation and slowing down its hydrolysis; reducing plasma clearance; improving drug dissociation and many more. Cyclopropane rings are widely found in marketed drugs, including cardiovascular drugs, central nervous system (CNS) drugs, anticancer drugs, autoimmune and anti-inflammatory drugs.

: RMC-9805; Revolution Medicines announced preliminary positive data for its RAS(ON) G12D-selective covalent inhibitor RMC-9805 in previously treated pancreatic ductal adenocarcinoma (PDAC) patients. The analysis showed that the disease control rate of PDAC patients treated with RMC-9805 was as high as 80%. RMC-9805 is a potential ‘first-in-class’ oral RAS(ON) G12D-selective inhibitor, that is being evaluated in trials to examine its efficacy and safety in patients with solid tumors carrying KRAS G12D mutations when used as a single agent or in combination with the pan-RAS inhibitor RMC-6236.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.